Tag: NF-κB

Deguelin, a Naturally Occurring Rotenoid, Acts as a Chemopreventive Agent

Head and neck squamous cell carcinoma (HNSCC) represents more than 5% of all cancers each year. In addition, breast cancer is a heterogeneous group of diseases. Approximately 60-70% of breast cancers express estrogen receptors (ER) and/or progesterone receptors (PR). About 20-30% of breast cancers have amplified levels of the...

CBL0137 is an Histone Chaperone FACT Inhibitor

Cancer harbors several characteristics, including high heterogeneity, diverse gene mutation, or rapid progression; consequently, treating cancer is difficult, and it easily relapses. Surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy show remarkable achievements. In particular, targeted therapies promote treatment. However, we have failed to treat cancer. Chemotherapy with or without...

IMD-0354 is a Selective IKKβ Inhibitor

IKKβ is an enzyme that is part of an intracellular signaling pathway activated by cytokines involved in triggering an immune response. Particularly, Phosphorylated IκB degrades and releases NF-κB through the ubiquitination pathway. Importantly, it enters the nucleus and participates in a variety of genes in inflammation and other immune...

PS315, an Allosteric PKC Inhibitor Binding to the PIF-Pocket

Members of the protein kinase C (PKC) family are regulated by phosphorylation and by an N-terminal extension of the catalytic domain. In addition, AGC kinases are a group of protein kinases comprising PKA, protein kinase G, and PKC families. They typically have three conserved phosphorylation sites. Besides, all PKCs...